US FTC expands probe into pharmacy benefit managers

Go back to US FTC expands probe into pharmacy benefit managers

CVS Health (CVS) already bakes in more than the worst-case scenario, TD Cowen 'would add here'

May 19, 2023 2:04 PM EDT

TD Cowen analyst Charles Rhyee reiterated an Outperform rating and $111 price target on CVS Health (NYSE: CVS) in a note Friday, telling investors that the current trough valuation "overly discounts" near-term risks.

"We would add here," said Rhyee. "Concerns over a number of... More